Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR-Reference-Cited by-同舟云学术

Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR

Published:2021 Issue:1 Volume:12 Page:103-109
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Riboldi Gustavo P.¹²³⁴⁵^ORCID,Zigweid Rachael⁶⁷⁸⁹,Myler Peter J.⁶⁷⁸⁹¹⁰,Mayclin Stephen J.¹¹⁸⁹¹²¹³,Couñago Rafael M.¹²³⁴⁵^ORCID,Staker Bart L.⁶⁷⁸⁹

Affiliation:

1. Centro de Química Medicinal (CQMED)

2. Centro de Biologia Molecular e Engenharia Genética (CBMEG)

3. Universidade Estadual de Campinas (UNICAMP)

4. Campinas

5. Brazil

6. Center for Infectious Disease Research

7. Seattle Children's Research Institute

8. Seattle

9. USA

10. Department of Pediatrics

11. Seattle Structural Genomics Center for Infectious Disease (SSGCID)

12. UCB

13. Bainbridge Island

Abstract

P218 is a potent inhibitor of M. ulcerans DHFR (K_i 3.2 nM).

Funder

Fundação de Amparo à Pesquisa do Estado de São Paulo

National Institute of Allergy and Infectious Diseases

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Wellcome Trust

Innovative Medicines Initiative

AbbVie

Bayer

Boehringer Ingelheim

Canada Foundation for Innovation

Eshelman Institute for Innovation, University of North Carolina at Chapel Hill

Genome Canada

Merck KGaA

Janssen Canada

Novartis Pharma

Ontario Ministry of Economic Development and Innovation

Pfizer

Takeda Pharmaceuticals U.S.A.

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/MD/D0MD00303D

Reference56 articles.

1. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease

2. Mycolactone: A Polyketide Toxin from Mycobacterium ulcerans Required for Virulence

3. Buruli ulcer (Mycobacterium ulcerans infection)

4. WHO Meeting on Buruli ulcer and other skin NTDs - Final Report, 2019

5. Buruli ulcer disease prevalence in Benin, West Africa: associations with land use/cover and the identification of disease clusters

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dihydrofolate Reductase (DHFR) Inhibitors: A Comprehensive Review;Current Medicinal Chemistry;2024-02

2. Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans;ACS Infectious Diseases;2024-01-31

3. Functionalization of 2,4-Dichloropyrimidines by 2,2,6,6-Tetramethylpiperidyl Zinc Base Enables Modular Synthesis of Antimalarial Diaminopyrimidine P218 and Analogues;The Journal of Organic Chemistry;2023-06-08

4. Combined metabolomics and network pharmacology to elucidate the mechanisms of Dracorhodin Perchlorate in treating diabetic foot ulcer rats;Frontiers in Pharmacology;2022-11-18